 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Liverpool School of Tropical Medicine |
| Street 1: | Pembroke Place |
| Street 2: | |
| City: | Liverpool |
| Province: | |
| Post Code: | L35QA |
| Country: | United Kingdom of Great Britain and Northern Ireland |
| Phone: | +44(0)151 705 3100 |
| Organization Email: | info@lstmed.ac.uk |
| Web Site: | http://www.lstmed.ac.uk |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 00083405 |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Organization Description: | |
| The Liverpool School of Tropical Medicine (LSTM) is the first institution dedicated to research and teaching in the field of tropical medicine and will be celebrating 125 years of global health impact in 2023. LSTM’s vision is for healthy lives across the world through improving health outcomes in disadvantaged populations globally, through partnership in research and education. The School’s work in combating diseases such as TB, HIV/AIDS, malaria, dengue and lymphatic filariasis is supported by a research portfolio of over £210 million and is at the forefront of infectious disease research. Attracting over 600 students from 68 countries, the School works in partnership with health ministries, universities, and research institutions worldwide to train the next generation of doctors, scientists, researchers and health professionals. Ending TB remains at the heart of our mission to improve health outcomes in disadvantaged populations globally. Our collaborative education, research, and knowledge exchange helps us reach more people with TB, making the global TB response more equitable, inclusive, gender-sensitive, and people-centred. |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Advocacy Civil Society and Community Engagement Research and Development Working on Community, Rights and Gender (CRG) Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 26 - 50 |
| Number of part-time staff who are directly involved with TB: | 26 - 50 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Attendance at a TB related event |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| LSTM TB staff are members of the UK Academics and Professionals to end TB network. We primarily campaign, advocate and educate the general public, public servants and politicians to improve UK policies on TB and devote more resources to TB research. | |
Geographical Reach | |
| Which country is your headquarters located in: | United Kingdom of Great Britain and Northern Ireland |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Cameroon Democratic Republic of the Congo Kenya Malawi Mozambique Nepal Nigeria Uganda United Kingdom of Great Britain and Northern Ireland Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: LSTM collaborates in Liverpool through LIV-TB, globally via the SPARKS network, and with fellow social scientists through SSHIFTB and the Union Working Group on Gender Equity in TB. At LSTM, TB researchers and healthcare professionals join the UK Academics and Professionals to end TB (UKAPTB) network, which works with policymakers, MPs, the UK’s UN Diplomatic Mission, and the TB Community, to create a coordinated, ambitious ask that contributes to a strong UNHLM on TB Political Declaration. Research: The LIGHT research programme, funded with UK aid, works with partners in Africa, and local and global stakeholders. It provides new evidence on the effectiveness of gender-sensitive approaches to health care for people with TB in urban, HIV-prevalent settings. New strategies to improve community-based diagnosis and care for people with TB are vitally important. The new START 4-All programme, funded by Unitaid,(link is external)(opens in a new tab) will develop and evaluate how to scale-up existing and new TB diagnostic combinations, to improve screening and increase access to testing in community and primary care settings. Our dear friend and colleague, the late Professor Luis Cuevas, started this programme. In Nepal, the Horizon 2020-funded IMPACT-TB project(link is external)(opens in a new tab), led by Dr Maxine Caws with the Birat Nepal Medical Trust(link is external)(opens in a new tab) (BNMT), has shown that actively finding people with TB, increases TB diagnoses, reducing care-seeking costs of people from underserved communities. Also in Nepal, LSTM’s Dr Tom Wingfield is working with BNMT on the Joint Global Health Trial’s funded ASCOT(link is external)(opens in a new tab) pilot trial to identify and address social determinants and consequences of TB(link is external)(opens in a new tab). TB is expected to account for 25% of all cases of antibiotic resistant disease, shortly. Professor Bertie Squire, Reader Eve Worrall, and Health Economist, Laura Rosu contributed to an LSTM-led economic evaluation of bedaquiline-containing multidrug resistant TB treatment, through the STREAM(link is external)(opens in a new tab) trial. It showed all-oral 9-month treatment plans worked but weren’t cost-effective for many countries, due to the cost of bedaquiline. LSTM’s Dr Naomi Walker is studying drug resistance patterns in Eastern DRC(link is external)(opens in a new tab), alongside the Catholic University of Bukavu, whilst her RNA (ribonucleic acid) analysis of immune responses, during treatment of HIV-associated TB, is funded by the Director’s Catalyst Award. LSTM’s Prof. Giancarlo Biagini’s team is investigating the pharmacology and resistance of TB drugs and working on pre-clinical projects to develop new inhibitors, funded by the MRC(link is external)(opens in a new tab) and GCRF(link is external)(opens in a new tab), with national and international academic partners and non-academic partners like TBAlliance(link is external)(opens in a new tab) and pharma. The team is also helping to develop a TB human challenge model to support new therapeutics and vaccine studies. Elsewhere, The Medical Research Foundation(link is external)(opens in a new tab) recently awarded Dr Tom Wingfield and Dr Celso Khosa(link is external)(opens in a new tab) a Dorothy Temple Cross International TB Collaboration Award to conduct the SAFEST-1 MDR-TB(link is external)(opens in a new tab) study evaluating whether video-observed therapy is suitable for people with drug-resistant TB in Mozambique. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | August 24, 2023 |
| Last updated: | April 1, 2025 |